Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：34

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[41] Motor symptoms and the quality of life of relapsing-remitting multiple sclerosis patients in a specialized center in South of Brazil [J].

Jorge, Francielle Fontana ;

Finkelsztejn, Alessandro ;

Rodrigues, Luciano Palmeiro .

ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (10) :895-899

[42] The influence of personality traits and coping strategies on the quality of life of patients with relapsing-remitting type of multiple sclerosis [J].

Krstic, Dragan ;

Krstic, Zvezdana D. ;

Stojanovic, Zvezdana ;

Kolundzija, Ksenija ;

Stojkovic, Mirjana ;

Dincic, Evica .

VOJNOSANITETSKI PREGLED, 2021, 78 (08) :805-810

[43] Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) [J].

Gold, Ralf ;

Giovannoni, Gavin ;

Phillips, J. Theodore ;

Fox, Robert J. ;

Zhang, Annie ;

Meltzer, Leslie ;

Kurukulasuriya, Nuwan C. .

MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) :57-66

[44] Health-related quality of life in Japanese patients with multiple sclerosis [J].

Niino, Masaaki ;

Fukumoto, Shoko ;

Okuno, Tatsusada ;

Sanjo, Nobuo ;

Fukaura, Hikoaki ;

Mori, Masahiro ;

Ohashi, Takashi ;

Takeuchi, Hideyuki ;

Shimizu, Yuko ;

Fujimori, Juichi ;

Kawachi, Izumi ;

Kira, Jun-Ichi ;

Takahashi, Eri ;

Miyazaki, Yusei ;

Mifune, Nobuhiro .

JOURNAL OF NEUROLOGY, 2023, 270 (02) :1011-1018

[45] Health-related quality of life in Japanese patients with multiple sclerosis [J].

Masaaki Niino ;

Shoko Fukumoto ;

Tatsusada Okuno ;

Nobuo Sanjo ;

Hikoaki Fukaura ;

Masahiro Mori ;

Takashi Ohashi ;

Hideyuki Takeuchi ;

Yuko Shimizu ;

Juichi Fujimori ;

Izumi Kawachi ;

Jun-ichi Kira ;

Eri Takahashi ;

Yusei Miyazaki ;

Nobuhiro Mifune .

Journal of Neurology, 2023, 270 :1011-1018

[46] Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study [J].

Ernst, Frank R. ;

Barr, Peri ;

Elmor, Riad ;

Wong, Schiffon L. .

CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) :2099-2106

[47] Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE) [J].

Gold, Ralf ;

Schlegel, Eugen ;

Elias-Hamp, Birte ;

Albert, Christian ;

Schmidt, Stephan ;

Tackenberg, Bjoern ;

Xiao, James ;

Schaak, Tom ;

Salmen, Hans Christian .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11

[48] Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC [J].

Berger, T. ;

Brochet, B. ;

Brambilla, L. ;

Giacomini, P. S. ;

Montalban, X. ;

Salgado, A. Vasco ;

Su, R. ;

Bretagne, A. .

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (04)

[49] Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial [J].

Robinson, D., Jr. ;

Zhao, N. ;

Gathany, T. ;

Kim, L. -L. ;

Cella, D. ;

Revicki, D. .

CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) :1121-1130

[50] Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies [J].

Havrdova, E. ;

Giovannoni, G. ;

Gold, R. ;

Fox, R. J. ;

Kappos, L. ;

Phillips, J. Theodore ;

Okwuokenye, M. ;

Marantz, J. L. .

EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (05) :726-733

← 1 2 3 4 5 →